Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Piceatannol
- DrugBank Accession Number
- DB08399
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Piceatannol (DB08399)
- Weight
- Average: 244.246
Monoisotopic: 244.073558866 - Chemical Formula
- C14H12O4
- Synonyms
- 3-hydroxyresveratol
- 3,3',4,5'-Tetrahydroxystilbene
- 3,3',4'5-Tetrahydroxystilbene
- 3,5,3',4'-tetrahydroxystilbene
- 4-[(E)-2-(3,5-dihydroxyphenyl)vinyl]benzene-1,2-diol
- Piceatannol
- External IDs
- C05901
- DB08399
- J61.264B
- NSC-365798
- NSC-622471
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UATP synthase subunit alpha, mitochondrial Not Available Humans UATP synthase subunit beta, mitochondrial Not Available Humans UATP synthase subunit gamma, mitochondrial Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetaminophen The serum concentration of Acetaminophen can be increased when it is combined with Piceatannol. Carbimazole The therapeutic efficacy of Carbimazole can be decreased when used in combination with Piceatannol. Follitropin The therapeutic efficacy of Follitropin can be decreased when used in combination with Piceatannol. Levothyroxine The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Piceatannol. Liothyronine The therapeutic efficacy of Liothyronine can be decreased when used in combination with Piceatannol. - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids.
- Kingdom
- Organic compounds
- Super Class
- Phenylpropanoids and polyketides
- Class
- Stilbenes
- Sub Class
- Not Available
- Direct Parent
- Stilbenes
- Alternative Parents
- Styrenes / Resorcinols / Catechols / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Organooxygen compounds / Hydrocarbon derivatives
- Substituents
- 1-hydroxy-2-unsubstituted benzenoid / 1-hydroxy-4-unsubstituted benzenoid / Aromatic homomonocyclic compound / Benzenoid / Catechol / Hydrocarbon derivative / Monocyclic benzene moiety / Organic oxygen compound / Organooxygen compound / Phenol
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- stilbenol (CHEBI:28814) / Diphenyl ethers, biphenyls, dibenzyls and stilbenes, Stilbenes (C05901) / Diphenyl ethers, biphenyls, dibenzyls and stilbenes (LMPK13090006)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 6KS3LS0D4F
- CAS number
- 10083-24-6
- InChI Key
- CDRPUGZCRXZLFL-OWOJBTEDSA-N
- InChI
- InChI=1S/C14H12O4/c15-11-5-10(6-12(16)8-11)2-1-9-3-4-13(17)14(18)7-9/h1-8,15-18H/b2-1+
- IUPAC Name
- 4-[(1E)-2-(3,5-dihydroxyphenyl)ethenyl]benzene-1,2-diol
- SMILES
- OC1=CC(\C=C\C2=CC=C(O)C(O)=C2)=CC(O)=C1
References
- Synthesis Reference
Alain Schouteeten, Sebastien Jus, Jean-Claude Vallejos, "Novel Process For The Synthesis Of (E)-Stilbene Derivatives Which Makes It Possible To Obtain Resveratrol And Piceatannol." U.S. Patent US20100004483, issued January 07, 2010.
US20100004483- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0004215
- KEGG Compound
- C05901
- PubChem Compound
- 667639
- PubChem Substance
- 99444870
- ChemSpider
- 581006
- BindingDB
- 50045936
- ChEBI
- 28814
- ChEMBL
- CHEMBL69863
- ZINC
- ZINC000000014036
- PDBe Ligand
- PIT
- Wikipedia
- Piceatannol
- PDB Entries
- 2jj1 / 4hd8 / 5u97 / 7ccv / 8fu2 / 8fu5 / 8srl / 8w43 / 8w48 / 8wrk
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data1 Not Yet Recruiting Treatment Acute Respiratory Distress Syndrome (ARDS) 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.097 mg/mL ALOGPS logP 2.12 ALOGPS logP 3.1 Chemaxon logS -3.4 ALOGPS pKa (Strongest Acidic) 8.41 Chemaxon pKa (Strongest Basic) -6.2 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 4 Chemaxon Polar Surface Area 80.92 Å2 Chemaxon Rotatable Bond Count 2 Chemaxon Refractivity 69.44 m3·mol-1 Chemaxon Polarizability 25.46 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9526 Blood Brain Barrier - 0.5495 Caco-2 permeable + 0.5789 P-glycoprotein substrate Non-substrate 0.5669 P-glycoprotein inhibitor I Non-inhibitor 0.9237 P-glycoprotein inhibitor II Non-inhibitor 0.9761 Renal organic cation transporter Non-inhibitor 0.9072 CYP450 2C9 substrate Non-substrate 0.7658 CYP450 2D6 substrate Non-substrate 0.9068 CYP450 3A4 substrate Non-substrate 0.6661 CYP450 1A2 substrate Inhibitor 0.9107 CYP450 2C9 inhibitor Inhibitor 0.6182 CYP450 2D6 inhibitor Non-inhibitor 0.9231 CYP450 2C19 inhibitor Non-inhibitor 0.9026 CYP450 3A4 inhibitor Inhibitor 0.5427 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.7651 Ames test Non AMES toxic 0.6502 Carcinogenicity Non-carcinogens 0.8962 Biodegradation Not ready biodegradable 0.7819 Rat acute toxicity 1.8860 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9444 hERG inhibition (predictor II) Non-inhibitor 0.8884
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 166.2774361 predictedDarkChem Lite v0.1.0 [M-H]- 173.9081361 predictedDarkChem Lite v0.1.0 [M-H]- 165.6972361 predictedDarkChem Lite v0.1.0 [M-H]- 163.04889 predictedDeepCCS 1.0 (2019) [M+H]+ 169.5414361 predictedDarkChem Lite v0.1.0 [M+H]+ 179.9121361 predictedDarkChem Lite v0.1.0 [M+H]+ 167.6694361 predictedDarkChem Lite v0.1.0 [M+H]+ 165.40689 predictedDeepCCS 1.0 (2019) [M+Na]+ 166.6470361 predictedDarkChem Lite v0.1.0 [M+Na]+ 175.0841361 predictedDarkChem Lite v0.1.0 [M+Na]+ 165.2746361 predictedDarkChem Lite v0.1.0 [M+Na]+ 171.50005 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Mitochondrial membrane ATP synthase (F(1)F(0) ATP synthase or Complex V) produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport complexes of the respiratory chain. F-type ATPases consist of two structural domains, F(1) - containing the extramembraneous catalytic core, and F(0) - containing the membrane proton channel, linked together by a central stalk and a peripheral stalk. During catalysis, ATP synthesis in the catalytic domain of F(1) is coupled via a rotary mechanism of the central stalk subunits to proton translocation. Subunits alpha and beta form the catalytic core in F(1). Rotation of the central stalk against the surrounding alpha(3)beta(3) subunits leads to hydrolysis of ATP in three separate catalytic sites on the beta subunits. Subunit alpha does not bear the catalytic high-affinity ATP-binding sites (By similarity). Binds the bacterial siderophore enterobactin and can promote mitochondrial accumulation of enterobactin-derived iron ions (PubMed:30146159)
- Specific Function
- Adp binding
- Gene Name
- ATP5F1A
- Uniprot ID
- P25705
- Uniprot Name
- ATP synthase subunit alpha, mitochondrial
- Molecular Weight
- 59750.06 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Mitochondrial membrane ATP synthase (F(1)F(0) ATP synthase or Complex V) produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport complexes of the respiratory chain. F-type ATPases consist of two structural domains, F(1) - containing the extramembraneous catalytic core, and F(0) - containing the membrane proton channel, linked together by a central stalk and a peripheral stalk. During catalysis, ATP synthesis in the catalytic domain of F(1) is coupled via a rotary mechanism of the central stalk subunits to proton translocation. Subunits alpha and beta form the catalytic core in F(1). Rotation of the central stalk against the surrounding alpha(3)beta(3) subunits leads to hydrolysis of ATP in three separate catalytic sites on the beta subunits
- Specific Function
- Angiostatin binding
- Gene Name
- ATP5F1B
- Uniprot ID
- P06576
- Uniprot Name
- ATP synthase subunit beta, mitochondrial
- Molecular Weight
- 56559.42 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Mitochondrial membrane ATP synthase (F(1)F(0) ATP synthase or Complex V) produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport complexes of the respiratory chain. F-type ATPases consist of two structural domains, F(1) - containing the extramembraneous catalytic core, and F(0) - containing the membrane proton channel, linked together by a central stalk and a peripheral stalk. During catalysis, ATP synthesis in the catalytic domain of F(1) is coupled via a rotary mechanism of the central stalk subunits to proton translocation. Part of the complex F(1) domain and the central stalk which is part of the complex rotary element. The gamma subunit protrudes into the catalytic domain formed of alpha(3)beta(3). Rotation of the central stalk against the surrounding alpha(3)beta(3) subunits leads to hydrolysis of ATP in three separate catalytic sites on the beta subunits
- Specific Function
- Proton-transporting atp synthase activity, rotational mechanism
- Gene Name
- ATP5F1C
- Uniprot ID
- P36542
- Uniprot Name
- ATP synthase subunit gamma, mitochondrial
- Molecular Weight
- 32995.665 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
Drug created at September 15, 2010 21:31 / Updated at June 12, 2020 16:52